+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 45Years
FEMALE
ID06533098

Randomized Study Comparing Nipocalimab and Intravenous Immunoglobulin in Pregnancies at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia

Led by Janssen Research & Development, LLC · Updated on 2026-11-03

50

Participants Needed

38

Research Sites

103 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia FNAIT, a condition affecting unborn and newborn babies. This Phase 3 randomized study compares nipocalimab with intravenous immunoglobulin IVIG treatment in pregnant women at risk of FNAIT. The trial is led by Janssen Research & Development, LLC and focuses on improving outcomes for fetuses and neonates facing serious bleeding risks. Pregnant participants with specific antibodies against HPA-1a andor HPA-5b are randomly assigned to receive either nipocalimab or IVIG. Nipocalimab is given intravenously starting between weeks 13 and 18 of pregnancy until delivery. IVIG is also given intravenously, starting at week 12 for high-risk pregnancies or week 20 for standard-risk pregnancies, along with oral prednisone which is tapered off after delivery based on the doctors judgment or participant tolerance. During the study, participants undergo regular assessments including blood tests to monitor platelet counts in their newborns, evaluation of bleeding events, and tracking of any adverse effects in both the mother and child. The main outcome is the presence of death, severe bleeding, or very low platelet counts in the fetus or newborn up to one week after birth. Longer-term follow-up includes developmental assessments of the infant at one and two years. The total study duration extends up to the end of 2029 with safety monitoring through the first 24 weeks postpartum and infant follow-up for up to 104 weeks.

CONDITIONS

Brief Title

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here